Skip to main content
Top
Published in: PharmacoEconomics 1/2014

01-01-2014 | Original Research Article

Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare

Authors: Fadia T. Shaya, Ian M. Breunig, Brian Seal, C. Daniel Mullins, Viktor V. Chirikov, Nader Hanna

Published in: PharmacoEconomics | Issue 1/2014

Login to get access

Abstract

Background

The incidence of hepatocellular carcinoma (HCC) is increasing in the USA and worldwide. Several treatments are available for patients diagnosed at any disease stage. It remains unclear how medical expenditures vary across patients who remain untreated or undergo different modes of therapy. We evaluate the comparative and cost effectiveness of treatment modalities for HCC from a Medicare perspective.

Methods

The Surveillance, Epidemiology, and End Results (SEER) registries and linked Medicare database with claims from Parts A/B were used to identify Medicare enrollees with initial diagnosis of HCC between 2000 and 2007 and followed through 2009. Patients were assigned to treatment modalities based on HCC staging systems: transplant, resection, liver directed, radiation, chemotherapy or no treatment. Survival benefits and cumulative Medicare expenditures were estimated in multivariate models, stratified by initial disease stage, to control for confounding. Cost-effectiveness ratios compared costs and benefits of the modalities across initial stages.

Results

Cancer stages I, II, III, IV and unstaged represented 24, 9, 14, 17 and 37 % of 11,047 patients, respectively. Fewer than 40 % received any treatment. Relative to no treatment, transplant was most effective in reducing mortality, followed by resection, liver directed, and radiation or chemotherapy. Resection tended to be most cost effective in early staged and unstaged patients; transplant was least cost effective. In stage IV patients, liver directed therapy was more cost effective than chemotherapy or radiation.

Conclusions

Survival benefit was attributable to all treatment modalities. More effective treatments incurred greater Medicare expenditures, but resection patients incurred the least expenditures per year of life gained.
Appendix
Available only for authorised users
Footnotes
1
Estimates may be somewhat biased if unidentified sorafenib use was systematically distributed across treatment modalities or no treatment within stages, and it had a significant impact on survival and costs. However, such bias is likely to be minimal given that sorafenib was approved for use by the FDA in December 2005 and our observation period spans the period from 2000 to 2009.
 
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef
2.
go back to reference Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485–91.PubMedCrossRef Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485–91.PubMedCrossRef
3.
go back to reference Shaw JJ, Shah SA. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev Gastroenterol Hepatol. 2011;5:365–70.PubMedCrossRef Shaw JJ, Shah SA. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev Gastroenterol Hepatol. 2011;5:365–70.PubMedCrossRef
5.
go back to reference Shah SA, Smith JK, Li YF, Ng SC, Carroll JE, Tseng JF. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer. 2011;117:1019–26.PubMedCrossRef Shah SA, Smith JK, Li YF, Ng SC, Carroll JE, Tseng JF. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer. 2011;117:1019–26.PubMedCrossRef
7.
go back to reference Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit Rev Oncol Hematol. 2012;83:216–24.PubMedCrossRef Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit Rev Oncol Hematol. 2012;83:216–24.PubMedCrossRef
8.
go back to reference Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRef Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRef
9.
go back to reference Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.PubMedCrossRef Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.PubMedCrossRef
10.
go back to reference Thomas MB, O’Beirne JP, Furuse J, Chan ATC, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol. 2008;15:1008–14.PubMedCrossRef Thomas MB, O’Beirne JP, Furuse J, Chan ATC, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol. 2008;15:1008–14.PubMedCrossRef
11.
go back to reference Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol. 2010;17:1247–56.PubMedCrossRef Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol. 2010;17:1247–56.PubMedCrossRef
12.
go back to reference Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50:89–99.PubMedCrossRef Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50:89–99.PubMedCrossRef
13.
go back to reference Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV3–18. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV3–18.
14.
go back to reference Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40:IV104–17.CrossRef Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40:IV104–17.CrossRef
16.
go back to reference Imbens GW. The role of the propensity score in estimating dose–response functions. Biometrika. 2000;87:706–10.CrossRef Imbens GW. The role of the propensity score in estimating dose–response functions. Biometrika. 2000;87:706–10.CrossRef
17.
go back to reference Lechner M. Identification and estimation of causal effects of multiple treatments under the conditional independence assumption. Econom Eval Labor Mark Policies ZEW Econ Stud. 2001;13:43–58.CrossRef Lechner M. Identification and estimation of causal effects of multiple treatments under the conditional independence assumption. Econom Eval Labor Mark Policies ZEW Econ Stud. 2001;13:43–58.CrossRef
18.
19.
go back to reference Griffiths RI, Gleeson ML, Danaes MD, O’Hagan A. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare. Value Health. 2012;15:656–63.PubMedCrossRef Griffiths RI, Gleeson ML, Danaes MD, O’Hagan A. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare. Value Health. 2012;15:656–63.PubMedCrossRef
20.
go back to reference White LA, Menzin J, Korn JR, et al. Medical care costs and survival associated with hepatocellular carcinoma among the elderly. Clin Gastroenterol Hepatol. 2012;10:547–54.PubMedCrossRef White LA, Menzin J, Korn JR, et al. Medical care costs and survival associated with hepatocellular carcinoma among the elderly. Clin Gastroenterol Hepatol. 2012;10:547–54.PubMedCrossRef
21.
go back to reference Nathan H, Schulick RD, Choti MA, et al. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799–805.PubMedCrossRef Nathan H, Schulick RD, Choti MA, et al. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799–805.PubMedCrossRef
Metadata
Title
Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare
Authors
Fadia T. Shaya
Ian M. Breunig
Brian Seal
C. Daniel Mullins
Viktor V. Chirikov
Nader Hanna
Publication date
01-01-2014
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 1/2014
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-013-0109-7

Other articles of this Issue 1/2014

PharmacoEconomics 1/2014 Go to the issue